- Home
- VALU vs LRMR Comparison
VALU vs LRMR Comparison
Compare VALU & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALU
- LRMR
- Stock Information
- Founded
- VALU 1931
- LRMR N/A
- Country
- VALU United States
- LRMR United States
- Employees
- VALU N/A
- LRMR N/A
- Industry
- VALU Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- VALU Finance
- LRMR Health Care
- Exchange
- VALU Nasdaq
- LRMR Nasdaq
- Market Cap
- VALU 340.4M
- LRMR 332.1M
- IPO Year
- VALU N/A
- LRMR N/A
- Fundamental
- Price
- VALU $36.86
- LRMR $3.66
- Analyst Decision
- VALU
- LRMR Strong Buy
- Analyst Count
- VALU 0
- LRMR 7
- Target Price
- VALU N/A
- LRMR $16.71
- AVG Volume (30 Days)
- VALU 3.3K
- LRMR 1.5M
- Earning Date
- VALU 12-12-2025
- LRMR 11-05-2025
- Dividend Yield
- VALU 3.50%
- LRMR N/A
- EPS Growth
- VALU 6.17
- LRMR N/A
- EPS
- VALU 2.26
- LRMR N/A
- Revenue
- VALU $34,801,000.00
- LRMR N/A
- Revenue This Year
- VALU N/A
- LRMR N/A
- Revenue Next Year
- VALU N/A
- LRMR N/A
- P/E Ratio
- VALU $15.96
- LRMR N/A
- Revenue Growth
- VALU N/A
- LRMR N/A
- 52 Week Low
- VALU $32.94
- LRMR $1.61
- 52 Week High
- VALU $55.01
- LRMR $6.91
- Technical
- Relative Strength Index (RSI)
- VALU 50.03
- LRMR 47.94
- Support Level
- VALU $36.03
- LRMR $3.32
- Resistance Level
- VALU $36.80
- LRMR $3.68
- Average True Range (ATR)
- VALU 0.84
- LRMR 0.26
- MACD
- VALU 0.06
- LRMR 0.04
- Stochastic Oscillator
- VALU 51.54
- LRMR 72.95
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.